Patient Satisfaction Regarding Home Injection Service for Somatostatin Analogues: A Survey Among Patients with a Neuroendocrine Tumour Abstract #1646

Introduction: Depot somatostatin analogues (SSA) Sandostatin LAR® (SL) and Somatuline Autogel® (SA) injections, are facilitated by a professional home injection service.
Aim(s): We have evaluated patient satisfactory in relation to this service.
Materials and methods: All patients with neuroendocrine tumours using depot SSA and home injection service ≥ 3 months were approached. A survey was designed with satisfaction related theorems with a five-point Likert scale, multiple choice and free text.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Wanda Geilvoet

To read results and conclusion, please login ...

Further abstracts you may be interested in

#215 Nurse Evaluation of Long-acting Somatostatin Analogue Injection Devices: A Quantitative Study
Introduction: The two major long-acting somatostatin analogues (SSA) available on the European market for the treatment of neuroendocrine tumors and acromegaly are Somatuline Autogel (SA) and Sandostatin LAR (LAR).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Hannah Kurth
#148 Near-complete regression of liver metastatic lesions in a patient with advanced pancreatic gastrinoma in response to somatostatin analogue therapy following cytoreductive surgery
Introduction: Although the majority of pancreatic NETs present with hepatic metastases, surgery with curative intent should be the first consideration. Cytoreductive surgery by resection of primary and secondary deposits may be of value in achieving local or endocrine symptoms control.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Dorota Dworakowska
Authors: Dworakowska D, Whyte M, Kane P, Patel A, ...
#2075 Phase 1 Pharmacokinetic and Pharmacodynamic Study of APOC, a New Controlled Release Formulation (CRF) of 15mg Octreotide Acetate in Healthy Male Volunteers
Introduction: Somatostatin analogues (SSAs) are considered the gold standard for systemic therapy of advanced neuroendocrine tumors (NETs). Octreotide is one of the SSAs most widely used in long-term therapies of NETs. There is increasing evidence that clinical benefits could be obtained with higher SSAs circulating levels but remain unreachable with current products without impacting significantly the quality of life of the patients. APOC is a new injectable controlled release technology containing Octreotide invented and developed by Ascil-Biopharm and designed to cover specifically these clinical unmet needs. It is presented as ready-to-use and can easily be manufactured at selected doses and durations in prefilled syringe.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Rosa Maria Antonijoan Arbós
#313 Effect of Somatostatin Analogues in the Control of Tumor Growth in Patients with Metastatic Lung Carcinoid Tumors
Introduction: Antitumor effect of Somatostatin analogues has been poorly documented in metastatic typical or atypical lung carcinoid tumors (LCT).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Pr Joël Guigay
#2106 Long-Acting Somatostatin Analogue (LA-SSA) Treatment Patterns in Patients Diagnosed with Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Grade 1 or 2 (G1/G2) in Sweden
Introduction: The main pharmacological treatment for metastatic GEP-NET G1/G2 is LA-SSA.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: PhD Daniel Granfeldt